neovascular glaucoma
Conditions
Interventions
Experimental group:Cyclocryotherapy combined with anti-VEGF therapy
Control group:Cyclocryotherapy
Sponsors
Shanghai First People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Over 18 years old, diagnosed with advanced NVG by a clinical specialist; 2. Vision less than 0.05, counting fingers, light perception, or no light perception; 3. Intraocular pressure >35mmHg after maximum anti-glaucoma medication; 4. Neovascularization of the iris/angle (stage II or above); 5. Has not previously undergone ciliary body cryotherapy; 6. Has no history of coronary heart disease, no history of cerebrovascular disease, no history of alcohol or tobacco abuse, and has normal coagulation function; 7. The subject has signed the informed consent form. After receiving a complete explanation of their participation in this study and fully understanding it, the subject voluntarily provides written consent to participate in this study and completes all scheduled visits.
Exclusion criteria
Exclusion criteria: 1. History of combined ocular tumors, uveitis, or scleral thinning; 2. Patients with active ocular infections or corneal erosion; 3. Individuals with insomnia, depression, central nervous system depression, or other psychiatric disorders; patients with myasthenia gravis or attention deficit hyperactivity disorder (ADHD); 4. Patients who have experienced cardiovascular events such as stroke, cerebral ischemia, or myocardial infarction within the past 6 months before screening; 5. Patients with systemic diseases, such as thyroid disorders, autoimmune diseases, or atopic dermatitis; 6. Presence of diseases or conditions in the target eye or systemically that the investigator believes could pose significant risk to the participant if they continue in the study (e.g., malignant hypertension, AIDS, malignant tumors, severe psychiatric, cardiovascular, neurological, respiratory, or digestive diseases, long-term corticosteroid use, immunodeficiency diseases, post-cardiac stent surgery, post-organ transplantation, etc.); 7. Individuals whose blood sugar or blood pressure cannot be controlled: fasting blood glucose exceeds 10 after medication, or blood pressure is higher than 180/110 mmHg; 8. Participants deemed unsuitable to continue the study by the researchers during the course of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of eyeball atrophy; | — |
Countries
China
Contacts
Public ContactQiaoyun Gong
Shanghai general hospital
Outcome results
None listed